Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence
NCT ID: NCT01769781
Last Updated: 2016-04-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
70 participants
INTERVENTIONAL
2013-01-31
2015-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Degarelix in the Treatment of Endometriosis Recurrence
NCT01712763
Letrozole in the Treatment of Severe and Recurrent Endometriosis
NCT00240942
Endometriosis Trial: Study of NBI-56418 in Endometriosis
NCT00109512
A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain
NCT01767090
GnRH-a on Angiogenesis of Endometriosis
NCT06106932
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
anastrazole
women with endometriosis recurrence will be treated with Leuprolide acetate 11,25mg plus anastrazole 1mg/day for three months
anastrazole
combined treatment with aromatase inhibitor (anastrazole) plus GnRH analog (leuprolide acetate) for three months
GnRH analog alone
women with endometriosis recurrence will be treated with leuprolide acetate 11.25mg
GnRH analog alone
treatment for three months with GnRH analog (leuprolide acetate) alone
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
anastrazole
combined treatment with aromatase inhibitor (anastrazole) plus GnRH analog (leuprolide acetate) for three months
GnRH analog alone
treatment for three months with GnRH analog (leuprolide acetate) alone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre for Endocrinology and Reproductive Medicine, Italy
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fabio Scarpellini
PRINCIPAL INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
marco sbracia, md
Role: STUDY_CHAIR
CERM-HUNGARIA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cerm-Hungaria
Rome, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CR013-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.